Vitamin K2 (Bones).

Vitamin D raises transcription of osteocalcin and matrix Gla protein, and vitamin K2 carboxylates those same proteins so they can bind calcium. One makes the protein, the other switches it on.

Carboxylated matrix Gla protein and osteocalcin are what steer calcium into bone matrix rather than into vessel wall and soft tissue. K2 therefore governs where a calcium dose ends up.

Magnesium is the cofactor for the hydroxylases that convert vitamin D to its active form, so it sits upstream of the K2 substrate supply. It is also a structural ion in the mineral that K2-dependent proteins help lay down.

The vitamin D receptor works as a heterodimer with the retinoid X receptor on the osteocalcin gene, so retinoid status shapes how much osteocalcin is made. K2 then carboxylates whatever is produced.

Large intakes of alpha-tocopherol interfere with the vitamin K quinone cycle and with gamma-carboxylation. A high vitamin E dose in the same formula can therefore work against K2 activity and normal clotting factor carboxylation.

Menaquinones are fat soluble and need lipid in the gut to form the micelles they travel in. A lipid carrier or a meal raises how much of the dose is taken up.

K1 and K2 feed the same carboxylase and the same quinone recycling cycle, and tissues convert part of a K1 dose into menaquinone-4. The two overlap rather than act as separate nutrients.

Alkaline phosphatase, the enzyme that prepares phosphate for mineral deposition, is a zinc metalloenzyme. Zinc therefore serves the deposition step that K2-dependent osteocalcin regulates.

Ascorbate is the cofactor for the prolyl and lysyl hydroxylases that build the collagen scaffold bone mineral deposits onto. K2 governs the mineral, vitamin C the matrix underneath it.

Bone is a collagen matrix that is then mineralised, and the covalent crosslinks holding that matrix together are formed by lysyl oxidase with copper at its active site. Menaquinone acts on the other side of the same matrix, carboxylating osteocalcin so it can bind calcium. The two support different steps of matrix quality and are commonly formulated together.

Manganese is the cofactor for the glycosyltransferases that assemble glycosaminoglycans in connective tissue and bone ground substance. Vitamin K2 contributes the carboxylation step that lets osteocalcin and matrix Gla protein bind calcium. Both feed the matrix side of bone, from different enzymes.

Boron affects how the body handles calcium and magnesium and appears at low levels in bone-support formulas for that reason. Vitamin K2 works on the carboxylation of bone matrix proteins rather than on mineral handling. The two are complementary in a formula rather than chemically interacting.

Silicon is found where new bone matrix meets mineral and is associated with connective tissue formation, though no specific human enzyme requiring it has been identified. Vitamin K2 carboxylates osteocalcin, one of the most abundant non-collagen proteins in that same matrix. They are paired on shared location in the tissue, not on a combination trial.

Roughly ninety percent of the organic matrix of bone is type I collagen, and osteocalcin is deposited into it. Carboxylated osteocalcin then binds calcium in the hydroxyapatite that forms around that scaffold. Supplying collagen substrate and the carboxylation cofactor addresses two ends of the same structure.

Bone mineral is calcium phosphate laid down as hydroxyapatite, so phosphate availability is part of the mineralisation account alongside calcium. Vitamin K2 carboxylates the Gla residues that bind that calcium. This is lattice chemistry, and it is not a claim about any measured endpoint.

MK-7 has a long isoprenoid tail and is strongly lipophilic, so it needs dietary fat and bile-driven micelle formation to be absorbed. An oil vehicle in a softgel, or fat in the accompanying meal, supplies that. This is a delivery relationship and applies to any long-chain oil.

Long-chain omega-3 triglycerides and menaquinone both enter mixed micelles and are packaged into chylomicrons, which is why K2 is often filled into an omega-3 softgel. The oil supplies the lipid phase that the vitamin needs. Co-formulation is a delivery choice, not an additive effect.

Menaquinone and ubiquinone share a naphthoquinone or benzoquinone head with a polyisoprenoid tail assembled from geranylgeranyl and farnesyl diphosphate units off the mevalonate pathway. That shared origin is why drugs that block the mevalonate pathway lower both. In a formula they are separately dosed lipophilic quinones with a common biosynthetic ancestry.

Natto fermentation produces both the long-chain menaquinone MK-7 and the fibrinolytic enzyme nattokinase, so the two often arrive from the same production stream. Some nattokinase preparations are deliberately K2-depleted and some are not, which matters for anyone counting total K intake. Read the pairing as a shared origin rather than a mechanistic synergy.

Members of the colonic microbiota, particularly Bacteroides and some lactic acid bacteria, produce menaquinones with side chains of varying length as part of their own respiration. How much of that colonic pool is absorbed by the host is debated, since absorption there is limited without bile. The relationship is a source one, and its size in humans is not settled.

Menaquinone output differs sharply between gut species, so the composition of the microbiota shapes how much is made in the colon. Bifidobacteria contribute to that community and to the fermentation environment around it. Any host contribution from this route is uncertain and should not be counted as a dose.

The vitamin K cycle depends on reducing equivalents to convert the epoxide back to the active hydroquinone, and NAD(P)H-dependent quinone reductases sit in that loop with flavin cofactors derived from riboflavin. This connects riboflavin status to the recycling capacity of vitamin K rather than to how much is absorbed. State it as mechanistic.